Jefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model
- Nov 18, 2025
- 1 min read
CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.
Coverage brought to you by










.png)
